Will the approval of one or more AD drug unleash the use of amyloid PET imaging?
Based on World Health Organization, Alzheimer's and dementia's diseases are the 7th leading cause of mortality worldwide1.
In the United States, Alzheimer's disease is the sixth leading cause of death2. Recently, a new Alzheimer's disease imaging drug has been approved and reimbursed in the US and in Japan. Amyloid PET imaging plays crucial role in the selection of patients that will likely benefit from these new treatments.
In this webinar, the main question is "Will the Approval of Novel Alzheimer's Disease Drugs Unleash the Use of Amyloid PET Imaging?" Prof. Barthel and Dr. Fujibayashi will reply to this main question. Prof. Barthel from Germany shares the European perspective on the challenges and opportunities related to the anticipated approval of Alzheimer's drugs in Europe. Dr. Fujibayashi from Japan navigates through the regulatory landscape of amyloid PET imaging in Japan by giving you the current status and future directions.
- World Health Organization - https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
- Alzheimer’s Disease | National Institutes of Health (NIH)
The European perspective on the challenges and opportunities related to the anticipated approval of Alzheimer's drugs in Europe
Prof Dr Henryk Barthel
Assistant Medical Director Brain PET and PET/MRI Department of Nuclear Medicine from the Leipzig University Medical Center
Navigate through the regulatory landscape of amyloid PET imaging in Japan by giving you the current status and future directions.
Dr Fujibayashi
Chief Technology Officer, CMI